At its (virtual) NextGen 2020 event, BMW today announced that the BMW iX, its new all-electric flagship previously known as the iNext, will launch at the end of 2021. Based on BMW’s fifth-generation eDrive technology, the iX will get a new look — and new kidney grille design — but its dimensions will be similar to the existing X5 or X6 SUVs. The company promises about 300 miles of range and 0-60 mph times of just under five seconds.

BMW has not released any pricing for the iX yet. Rumors earlier this year pegged it at close to $100,000.

The company says it will have more than a million electrified cars on roads by the end of 2021. Right now, about 13% of all BMW and MINI models registered in Europe are either all-electric or plug-in hybrids, and the expectation is that by 2030, that number will increase to 50%.

Coming next year, that lineup will include a number of new additions to the company’s electrified fleet, but the iX is clearly the focus here, though the next-generation eDrive system will also feature in the 2021 i4, for example, and BMW is experimenting with a 5-Series model that features three of these new motors for a maximum power output of 720 hp (we’re still talking about a company that made its name by combining performance and luxury, after all).

With DC fast charging at up to 200 kW, the iX should be able to charge from 10 to 80% in about 40 minutes. A 10-minute top-off at a fast-charging station should be enough for about 75 miles. For the most part, that’s in line with comparable electric cars, though Tesla’s V3 Supercharging promises somewhat faster recharge times and others can charge at more than 200 kW.

In addition to being BMW’s electric flagship, the iNext/iX unsurprisingly also showcases the company’s latest technology innovations. That’s obviously no surprise, given that BMW has used various iterations of its iNext concept car to think about how to best integrate new technologies into its next-generation of vehicles.

For the iX, these include all the standard driver assistance systems you’d expect today (though details there are scarce), a head-up display and large screens with a 12.3-inch instrument cluster and a 14.9-inch control display. But what’s maybe even more interesting here is the company’s over philosophy which the company describes as “shy tech.”

“Shy tech refers to technology that remains largely in the background and only reveals its functions when they are being used,” the company says in today’s announcement. “On entry into the car, the function in question is the electrically powered door locks. The interior welcomes the occupants of all five seats with a luxurious lounge-style ambience, and provides the space required to explore new ways of using time spent inside the car.”

For the most part, the user interface also strips away all distractions to allow the driver to focus on the road.

It’s no secret that BMW would like to — at some point — allow drivers to lounge in their self-driving cars. BMW hasn’t talked about the car’s driver assistant features yet, so that future hasn’t quite arrived just yet, but the company argues that by leaving out the usual center tunnel, it can provide a more “airy and specious feel” that “accentuates the lounge-style ambience and long-distance comfort provided by the interior.”

In many ways, the iX is the current apotheosis of BMW’s electric ambitions, and it is worth noting that, unlike others, the company is keeping a lot of the development in-house. That includes its Dingolfing plant, but as the company noted today, it is also developing its own battery cells and a new pilot plant for building its batteries near Munich should open in 2022. “This pilot plant will make BMW the first carmaker to cover the entire process chain for electric driving in-house,” BMW argues.

This wouldn’t be a major tech launch if it didn’t also feature a 5G aspect and indeed, the iX will feature built-in 5G connectivity, which should make it among the first — if not the first — 5G-enabled production car. Ideally, that means higher bandwidth and lower latency when the car needs to connect to the BMW cloud. But as we’ve all learned from recent phone launches, 5G is currently more of a buzzword than game-changing technology. What’s maybe more important here is that it may enable new C-V2X (Cellular Vehicle to Everything) solutions that will allow vehicles to communicate with each other and nearby smartphones — even without a mobile network.

The “Stepper Motor Market Research Report: By Type, Motion Control, End Use – Global Industry Analysis and Growth Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering.

Wall Street legend Whitney Tilson says there’s a huge new tech trend coming – and he’s revealing his #1 pick for free.

(Bloomberg) — Pfizer Inc. Chief Executive Officer Albert Bourla pocketed about $5.6 million after selling stock, the latest executive to reap the rewards of insider share transactions amid a vaccine-fueled rally for some pharmaceutical companies.Bourla disposed of more than 130,000 shares on Monday, according to a filing with the U.S. Securities and Exchange Commission. Sally Susman, executive vice president and chief corporate affairs officer at Pfizer, also offloaded about $1.8 million in stock.Pfizer’s shares soared that day after a report on results from its experimental vaccine with partner BioNTech SE. Anthony Fauci, the top U.S. infectious-disease specialist described the findings as “extraordinary” and regulators on both sides of the Atlantic could clear the vaccine for emergency use imminently.Both executives’ sales were done under prearranged 10b5-1 trading plans, which let people schedule sales in advance at certain times or prices, absolving themselves from accusations of insider trading. Public-company executives typically receive a considerable share of their compensation in the form of stock, and the vast majority periodically sell part of their holdings.A Pfizer spokeswoman said the sales were part of the executives’ personal financial planning. Bourla authorized the sale in August and Susman in November 2019, provided the stock reached a certain price.Still, some governance watchdogs criticize executive sales generally, and trading plans in particular, asking why bosses would dispose of stock if they think the price might be higher in the future. Moderna Inc., for example, has received scrutiny as executives sold large amounts of stock throughout the spring and the summer.Read more: Moderna executive stakes trimmed even before latest lockup liftsModerna’s CEO Stephane Bancel has sold more than half a million shares this year, but the value of his stake has swelled as the stock has rallied more than 300% in 2020. Moderna is also slated to release its own late-stage Covid-19 vaccine data sometime this month that could push prices higher.Moderna didn’t immediately respond to emailed requests seeking comment.(Updates with Susman title in second paragraph and consequences of Pfizer study in third)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Campuswire was in a fortuitous spot when colleges and universities across the world shut down on short notice because of the threat of coronavirus. Founded by Tade Oyerinde in 2018, Campuswire is a virtual solution for any teacher who wants to digitize their internal classroom communications, from Q&A time to the lecture itself. Campuswire is now used at more than 300 universities among 200,000 students, Oyerinde tells me.

The nationally recognized attorneys from Baron & Budd, P.C. alongside Seagle Law have filed lawsuits against the Chemours Company and Dupont on behalf of 87 individuals who own property near the Fayetteville Works plant. These lawsuits have been filed as part of a consolidated action where hundreds of similar lawsuits are currently being litigated. According to the lawsuit, Chemours and Dupont have contaminated the groundwater near the Fayetteville Works plant with toxic per- and polyfluoroalkyl substances (PFASs), including GenX. Many private drinking water wells have been affected by this contamination.

The clock just started on the biggest financial event in 20 years. Fortunes will be made and lost. Here’s how to prepare – before 2020 comes to an end

(Bloomberg) — Gold headed for its second loss in three days as gains in the dollar and technology stocks diminished demand for the metal as a haven asset.The Bloomberg Dollar Spot Index rose as much as 0.4%, holding on to its recovery from the 2018 lows reached on Monday. U.S. stocks rose, with the resurgent coronavirus spurring traders to pile back into companies with solid balance sheets and products that benefit from social distancing. Yields on 10-year Treasuries climbed to within a few basis points of 1% on Tuesday. The firmer U.S. dollar and rising bond yields are “generating headwind” for gold, Commerzbank AG analyst Carsten Fritsch said in a note.Still, with the number of new Covid cases rising, governments and central banks are likely to remain under pressure to take further stimulus measures until widespread vaccinations can be carried out, benefiting gold, Fritsch said.A resurgence of cases and deaths continued in Europe, with Germany reporting its highest daily fatalities since mid-April. New York City’s average of people testing positive for Covid-19 is approaching the safety threshold that would force a shutdown of schools. The developer of Russia’s flagship shot said it shows a 92% efficacy rate in preventing infections, days after Pfizer Inc. reported a similar breakthrough for its rival vaccine.“The biggest reason for another abrupt drop in gold prices would be more good news on the Covid-19 vaccine front,” James Steel, chief precious metals analyst at HSBC Holdings Plc, said in a note.Spot gold fell 0.7% $1,864.31 an ounce by 10:53 a.m. in New York. Prices advanced 0.8% on Tuesday after slumping 4.5% a day earlier.Silver, palladium and platinum also turned lower on Wednesday, while the Bloomberg Dollar Spot Index rose 0.3%.Some analysts said moves across financial markets on Monday in response to vaccine optimism may have gone too far, with experts pointing to hurdles. Investors are also keeping an eye on stimulus prospects and the U.S. presidential transition, as Donald Trump hasn’t dropped his challenge to the election result.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

Honda says it’ll be the first brand to mass produce cars capable of level 3 self-driving.

A joint report by researchers in Australia and China has identified ways to improve cooperation between the two nations, with economic spinoffs.

Search for private jet membership. The affordable price makes these private jet offers hard to resist

Hannah Clarke’s family have renewed their push for coercive control to be criminalised as the murdered mother is named one of Marie Claire’s Women of the Year.

Policies in police watch houses are among the issues expected to be considered by an inquest into the death of an Indigenous woman in Brisbane in September.

Low rates won’t last long – Lock in a lower mortgage rate and save thousands a year before it’s too late.

Dow (NYSE:DOW) announced the winners of the 2020 Packaging Innovation Awards recognizing breakthrough packaging achievements in design, technology, sustainability and user experience.

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”).

Search for new 2020 tacoma pickup truck. The affordable price makes this truck hard to resist.

Ametros announces that Porter Leslie has been promoted to CEO as Marques Torbert transitions to Chair of its board of directors.

DEERFIELD, Ill., Nov. 11, 2020 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery, including through the application of digital technologies to improve patient outcomes, today announced it plans to release financial results from the third quarter 2020 on Wednesday, November 11, 2020, after the market closes. Surgalign will host a conference call and audio webcast at 4:30 p.m. Eastern Time the same day. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 8371139. The webcast can be accessed through the investor section of Surgalign’s website at surgalign.com/investors/. A replay of the conference call will be available on Surgalign’s website for at least one month following the call.Virtual Investor DayAs previously announced, the Company will host a virtual investor day on Thursday, November 12, 2020 from 1:00 – 3:00am ET (10:00am – 12:00pm PT).To register for the event, please use the following link: Investor Day Registration. After you complete registration, you will receive a confirmation email that will include all of the details needed to access the webcast or to dial in by phone.The live webcast, including audio, video and presentation slides, will be accessible on www.surgalign.com/investors/ at the time of the meeting. Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on www.surgalign.com/investors/ following the conclusion of the event.About Surgalign Holdings, Inc.Surgalign Holdings, Inc. is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company is building off a legacy of high quality and differentiated products, and continues to invest in clinically validated innovation to deliver better surgical outcomes and improve patient’s lives. Surgalign markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. Surgalign, a member of AdvaMed, is headquartered in Deerfield, THE, with commercial, innovation and design centers in San Diego, THAT, Marquette, ME, and Wurmlingen, Germany. Learn more at www.surgalign.com and connect on LinkedIn and Twitter.Forward Looking StatementThis communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting Surgalign’s website at www.surgalign.com or the SEC’s website at www.sec.gov.Jonathon Singer Investor and Media Contact [email protected] +1 224 303 4651

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Nov. 11, 2020 (GLOBE NEWSWIRE) — Caldas Gold Corp. (TSX-V: CGC) (OTCQX: ALLXF) is pleased to announce that it has satisfied the escrow release conditions in respect of its US$83,066,000 private placement offering of 83,066 subscription receipts (“Subscription Receipts”) completed on August 26, 2020 (the “Offering”). Among other escrow release conditions, the Company filed and obtained a receipt (the “Receipt”) for a final short form prospectus (the “Prospectus”) in each of the provinces of Canada, except Québec, qualifying for distribution 83,066 units of the Company (the “Units”), with each Unit comprising senior secured gold-linked notes in an aggregate principal amount of US$1,000 (the “Notes”) and 200 common share purchase warrants (the “Warrants”). The Notes and Warrants are issuable for no additional consideration upon the conversion of the Subscription Receipts, with the Units separating into Notes and Warrants immediately upon issue. The Offering was conducted by a syndicate of agents co-led by Scotiabank and Canaccord Genuity Corp.As a result of satisfying the escrow release conditions, the Subscription Receipts shall be converted, and the Notes and Warrants underlying the Subscription Receipts will be issued, effective at 5:00 p.m. (Toronto time) on Wednesday, November 18, 2020.A copy of the Prospectus, including the documents incorporated by reference therein, is available under the Company’s SEDAR profile at www.sedar.com.About Caldas GoldCaldas Gold is a Canadian junior mining company currently advancing a major expansion and modernization of its underground mining operations at its Marmato Project in the Department of Caldas, Colombia. Caldas Gold also owns 100% of the Juby Project, an advanced exploration-stage gold project located within the Shining Tree area in the southern part of the Abitibi greenstone belt about 100 km south-southeast of the Timmins gold camp.Additional information on Caldas Gold can be found on its website at www.caldasgold.ca and by reviewing its profile on SEDAR at www.sedar.com.Forward-Looking InformationThis press release contains forward-looking statements and information within the meaning of applicable securities legislation (collectively referred to herein as “forward-looking statements”). Forward-looking statements, which are all statements other than statements of historical fact, include, but are not limited to, the issuance of the Notes and Warrants underlying the Subscription Receipts. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Caldas Gold to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements include the risk factors as described under the caption “Risk Factors” in the Prospectus and in the Company’s annual information form dated August 17, 2020, each of which are available for view on SEDAR at www.sedar.com. Forward-looking statements contained herein are made as of the date of this press release and Caldas Gold disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management’s estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.This press release is not, and should not be construed as, an offer to sell or acquire any securities in any jurisdiction.For Further Information, Contact:Mike Davies Chief Financial Officer (416) 360-4653 [email protected] announcement does not constitute an offer of securities for sale in the United States, nor may any securities referred to herein be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933 as amended (the “Securities Act”) and the rules and regulations thereunder. The securities referred to herein have not been registered pursuant to the Securities Act and there is no intention to register any of the securities in the United States or to conduct a public offering of securities in the United States.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

As the trillion-dollar office economy dies and the at-home revolution begins, investors are preparing for a massive shift.

Global Ligament Stabilizers Market to Reach $3. 1 Billion by 2027. Amid the COVID-19 crisis, the global market for Ligament Stabilizers estimated at US$2. 3 Billion in the year 2020, is projected to reach a revised size of US$3.New York, Nov. 11, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the reportGlobal Ligament Stabilizers Industry” – https://www.reportlinker.com/p05961015/?utm_source=GNW 1 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027. Grade 1, one of the segments analyzed in the report, is projected to record a 4.9% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Grade 2 segment is readjusted to a revised 4.5% CAGR for the next 7-year period. The U.S. Market is Estimated at $664.3 Million, While China is Forecast to Grow at 4.3% CAGR The Ligament Stabilizers market in the U.S. is estimated at US$664.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$545.5 Million by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR. Grade 3 Segment to Record 4.1% CAGR In the global Grade 3 segment, USA, Canada, Japan, China and Europe will drive the 4.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$394.9 Million in the year 2020 will reach a projected size of US$524.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$353.5 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 179-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, * 3M Company * Bauerfeind AG * BREG, Inc. * BSN Medical GmbH * DeRoyal Industries, Inc. * DJO Global, Inc. * Medi GmbH & Co. KG * Ossur HF * Otto Bock Healthcare GmbH * Thuasne Group Read the full report: https://www.reportlinker.com/p05961015/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Ligament Stabilizer Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: Ligament Stabilizers Global Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 Table 2: Ligament Stabilizers Global Retrospective Market Scenario in US$ Million by Region/Country: 2012-2019 Table 3: Ligament Stabilizers Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 Table 4: Grade 1 (Injury Type) World Market by Region/Country in US$ Million: 2020 to 2027 Table 5: Grade 1 (Injury Type) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019 Table 6: Grade 1 (Injury Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 Table 7: Grade 2 (Injury Type) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027 Table 8: Grade 2 (Injury Type) Historic Market Perspective by Region/Country in US$ Million: 2012 to 2019 Table 9: Grade 2 (Injury Type) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027 Table 10: Grade 3 (Injury Type) Geographic Market Spread Worldwide in US$ Million: 2020 to 2027 Table 11: Grade 3 (Injury Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2012 to 2019 Table 12: Grade 3 (Injury Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 Table 13: Knee Braces & Supports (Product Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2020 to 2027 Table 14: Knee Braces & Supports (Product Type) Market Historic Review by Region/Country in US$ Million: 2012 to 2019 Table 15: Knee Braces & Supports (Product Type) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027 Table 16: Foot and Ankle Braces & Supports (Product Type) World Market by Region/Country in US$ Million: 2020 to 2027 Table 17: Foot and Ankle Braces & Supports (Product Type) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019 Table 18: Foot and Ankle Braces & Supports (Product Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 Table 19: Shoulder Braces & Supports (Product Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2020 to 2027 Table 20: Shoulder Braces & Supports (Product Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2012 to 2019 Table 21: Shoulder Braces & Supports (Product Type) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027 Table 22: Spinal Orthoses (Product Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2020 to 2027 Table 23: Spinal Orthoses (Product Type) Global Historic Demand in US$ Million by Region/Country: 2012 to 2019 Table 24: Spinal Orthoses (Product Type) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 Table 25: Wrist & Hand Braces & Supports (Product Type) World Market by Region/Country in US$ Million: 2020 to 2027 Table 26: Wrist & Hand Braces & Supports (Product Type) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019 Table 27: Wrist & Hand Braces & Supports (Product Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Ligament Stabilizer Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 28: United States Ligament Stabilizers Market Estimates and Projections in US$ Million by Injury Type: 2020 to 2027 Table 29: Ligament Stabilizers Market in the United States by Injury Type: A Historic Review in US$ Million for 2012-2019 Table 30: United States Ligament Stabilizers Market Share Breakdown by Injury Type: 2012 VS 2020 VS 2027 Table 31: United States Ligament Stabilizers Market Estimates and Projections in US$ Million by Product Type: 2020 to 2027 Table 32: Ligament Stabilizers Market in the United States by Product Type: A Historic Review in US$ Million for 2012-2019 Table 33: United States Ligament Stabilizers Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 CANADA Table 34: Canadian Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Injury Type: 2020 to 2027 Table 35: Canadian Ligament Stabilizers Historic Market Review by Injury Type in US$ Million: 2012-2019 Table 36: Ligament Stabilizers Market in Canada: Percentage Share Breakdown of Sales by Injury Type for 2012, 2020, and 2027 Table 37: Canadian Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Product Type: 2020 to 2027 Table 38: Canadian Ligament Stabilizers Historic Market Review by Product Type in US$ Million: 2012-2019 Table 39: Ligament Stabilizers Market in Canada: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 JAPAN Table 40: Japanese Market for Ligament Stabilizers: Annual Sales Estimates and Projections in US$ Million by Injury Type for the Period 2020-2027 Table 41: Ligament Stabilizers Market in Japan: Historic Sales Analysis in US$ Million by Injury Type for the Period 2012-2019 Table 42: Japanese Ligament Stabilizers Market Share Analysis by Injury Type: 2012 VS 2020 VS 2027 Table 43: Japanese Market for Ligament Stabilizers: Annual Sales Estimates and Projections in US$ Million by Product Type for the Period 2020-2027 Table 44: Ligament Stabilizers Market in Japan: Historic Sales Analysis in US$ Million by Product Type for the Period 2012-2019 Table 45: Japanese Ligament Stabilizers Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 CHINA Table 46: Chinese Ligament Stabilizers Market Growth Prospects in US$ Million by Injury Type for the Period 2020-2027 Table 47: Ligament Stabilizers Historic Market Analysis in China in US$ Million by Injury Type: 2012-2019 Table 48: Chinese Ligament Stabilizers Market by Injury Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 Table 49: Chinese Ligament Stabilizers Market Growth Prospects in US$ Million by Product Type for the Period 2020-2027 Table 50: Ligament Stabilizers Historic Market Analysis in China in US$ Million by Product Type: 2012-2019 Table 51: Chinese Ligament Stabilizers Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 EUROPE Market Facts & Figures European Ligament Stabilizer Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 52: European Ligament Stabilizers Market Demand Scenario in US$ Million by Region/Country: 2020-2027 Table 53: Ligament Stabilizers Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2012-2019 Table 54: European Ligament Stabilizers Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 Table 55: European Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Injury Type: 2020-2027 Table 56: Ligament Stabilizers Market in Europe in US$ Million by Injury Type: A Historic Review for the Period 2012-2019 Table 57: European Ligament Stabilizers Market Share Breakdown by Injury Type: 2012 VS 2020 VS 2027 Table 58: European Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Product Type: 2020-2027 Table 59: Ligament Stabilizers Market in Europe in US$ Million by Product Type: A Historic Review for the Period 2012-2019 Table 60: European Ligament Stabilizers Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 FRANCE Table 61: Ligament Stabilizers Market in France by Injury Type: Estimates and Projections in US$ Million for the Period 2020-2027 Table 62: French Ligament Stabilizers Historic Market Scenario in US$ Million by Injury Type: 2012-2019 Table 63: French Ligament Stabilizers Market Share Analysis by Injury Type: 2012 VS 2020 VS 2027 Table 64: Ligament Stabilizers Market in France by Product Type: Estimates and Projections in US$ Million for the Period 2020-2027 Table 65: French Ligament Stabilizers Historic Market Scenario in US$ Million by Product Type: 2012-2019 Table 66: French Ligament Stabilizers Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 GERMANY Table 67: Ligament Stabilizers Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Injury Type for the Period 2020-2027 Table 68: German Ligament Stabilizers Historic Market Analysis in US$ Million by Injury Type: 2012-2019 Table 69: German Ligament Stabilizers Market Share Breakdown by Injury Type: 2012 VS 2020 VS 2027 Table 70: Ligament Stabilizers Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Product Type for the Period 2020-2027 Table 71: German Ligament Stabilizers Historic Market Analysis in US$ Million by Product Type: 2012-2019 Table 72: German Ligament Stabilizers Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 ITALY Table 73: Italian Ligament Stabilizers Market Growth Prospects in US$ Million by Injury Type for the Period 2020-2027 Table 74: Ligament Stabilizers Historic Market Analysis in Italy in US$ Million by Injury Type: 2012-2019 Table 75: Italian Ligament Stabilizers Market by Injury Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 Table 76: Italian Ligament Stabilizers Market Growth Prospects in US$ Million by Product Type for the Period 2020-2027 Table 77: Ligament Stabilizers Historic Market Analysis in Italy in US$ Million by Product Type: 2012-2019 Table 78: Italian Ligament Stabilizers Market by Product Type: Percentage Breakdown of Sales for 2012, 2020, and 2027 UNITED KINGDOM Table 79: United Kingdom Market for Ligament Stabilizers: Annual Sales Estimates and Projections in US$ Million by Injury Type for the Period 2020-2027 Table 80: Ligament Stabilizers Market in the United Kingdom: Historic Sales Analysis in US$ Million by Injury Type for the Period 2012-2019 Table 81: United Kingdom Ligament Stabilizers Market Share Analysis by Injury Type: 2012 VS 2020 VS 2027 Table 82: United Kingdom Market for Ligament Stabilizers: Annual Sales Estimates and Projections in US$ Million by Product Type for the Period 2020-2027 Table 83: Ligament Stabilizers Market in the United Kingdom: Historic Sales Analysis in US$ Million by Product Type for the Period 2012-2019 Table 84: United Kingdom Ligament Stabilizers Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 REST OF EUROPE Table 85: Rest of Europe Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Injury Type: 2020-2027 Table 86: Ligament Stabilizers Market in Rest of Europe in US$ Million by Injury Type: A Historic Review for the Period 2012-2019 Table 87: Rest of Europe Ligament Stabilizers Market Share Breakdown by Injury Type: 2012 VS 2020 VS 2027 Table 88: Rest of Europe Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Product Type: 2020-2027 Table 89: Ligament Stabilizers Market in Rest of Europe in US$ Million by Product Type: A Historic Review for the Period 2012-2019 Table 90: Rest of Europe Ligament Stabilizers Market Share Breakdown by Product Type: 2012 VS 2020 VS 2027 ASIA-PACIFIC Table 91: Ligament Stabilizers Market in Asia-Pacific by Injury Type: Estimates and Projections in US$ Million for the Period 2020-2027 Table 92: Asia-Pacific Ligament Stabilizers Historic Market Scenario in US$ Million by Injury Type: 2012-2019 Table 93: Asia-Pacific Ligament Stabilizers Market Share Analysis by Injury Type: 2012 VS 2020 VS 2027 Table 94: Ligament Stabilizers Market in Asia-Pacific by Product Type: Estimates and Projections in US$ Million for the Period 2020-2027 Table 95: Asia-Pacific Ligament Stabilizers Historic Market Scenario in US$ Million by Product Type: 2012-2019 Table 96: Asia-Pacific Ligament Stabilizers Market Share Analysis by Product Type: 2012 VS 2020 VS 2027 REST OF WORLD Table 97: Rest of World Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Injury Type: 2020 to 2027 Table 98: Rest of World Ligament Stabilizers Historic Market Review by Injury Type in US$ Million: 2012-2019 Table 99: Ligament Stabilizers Market in Rest of World: Percentage Share Breakdown of Sales by Injury Type for 2012, 2020, and 2027 Table 100: Rest of World Ligament Stabilizers Market Estimates and Forecasts in US$ Million by Product Type: 2020 to 2027 Table 101: Rest of World Ligament Stabilizers Historic Market Review by Product Type in US$ Million: 2012-2019 Table 102: Ligament Stabilizers Market in Rest of World: Percentage Share Breakdown of Sales by Product Type for 2012, 2020, and 2027 IV. COMPETITION Total Companies Profiled: 38 Read the full report: https://www.reportlinker.com/p05961015/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you needinstantly, in one place. __________________________ CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

The FA will conform to its own new diversity code in the recruitment of a new chairman to succeed Greg Clarke, meaning one male and one female BAME candidate are expected to be shortlisted for the job. FA chief executive Mark Bullingham says the governing body hope to make an appointmentas soon as possibleand confirmed the recruitment process will beopen and conform to the Diversity Code”. The new code, which was launched last month, requires at least one male and one female Black, Asian or of Mixed-Heritage candidate to be shortlisted for open positions, provided applicants who meet the job specifications apply.

Albion Technology & General VCT PLC Interim Management Statement LEI code: 213800TKJUY376H3KN16Introduction I am pleased to present Albion Technology & General VCT PLC’s (the “Company”) interim management statement for the period from 1 July 2020 to 30 September 2020.Performance and dividends The Company’s unaudited net asset value (NAV) as at 30 September 2020 was £87.0 million or 78.75 pence per share (excluding treasury shares), an increase of 0.90 pence per share (1.2 per cent.) since 30 June 2020.After accounting for the special dividend of 9.00 pence per share paid on 30 October 2020 to shareholders on the register on 9 October 2020, the NAV is 69.75 pence per share.A second interim dividend for the year ending 31 December 2020 of 1.95 pence per Ordinary share is to be paid on 31 December 2020 to shareholders on the register on 4 December 2020, resulting in total dividends of 12.95 pence per share for the year.Share buy-backs There were no share buy-backs during the period from 1 July 2020 to 30 September 2020.It remains the Board’s policy to buy back shares in the market, subject to the overall constraint that such purchases are in the Company’s interest, including the maintenance of sufficient resources for investment in existing and new portfolio companies and the continued payment of dividends to shareholders. It is the Board’s intention for such buy-backs to be at around a 5 per cent. discount to the most recently announced net asset value, so far as market conditions and liquidity permit.Portfolio The following investments have been made during the period from 1 July 2020 to 30 September 2020:New investment£’000Activity The Voucher Market Limited (T/A WeGift)1,020A cloud platform that enables corporates to purchase digital gift cards and to distribute them to employees and customers Total new investments1,020 Further investments£’000Activity Quantexa Limited1,967Network analytics platform to detect financial crime Oxsensis Limited1,082A developer and producer of industrial sensors for use in ultra-high temperature environments uMotif Limited426A patient engagement and data capture platform for use in real world and observational research Phrasee Limited288AI platform that generates optimised marketing campaigns The Evewell (Harley Street) Limited52Operator of a women’s health centre focusing on fertility ePatient Network Limited (T/A Raremark)46Online community connecting people affected by rare diseases Total further investments3,861 Top ten holdings as at 30 September 2020: InvestmentCarrying value £’000% of net asset valueActivity Quantexa Limited 7,9789.2Network analytics platform to detect financial crime Radnor House School (TopCo) Limited 4,6115.3Independent school for children aged 2.5-18 Chonais River Hydro Limited 3,9154.5Owner and operator of a 2 MW hydro-power scheme in the Scottish Highlands Oxsensis Limited 3,6974.3A developer and producer of industrial sensors for use in ultra-high temperature environments Proveca Limited 3,6214.2Reformulation of paediatric medicines Gharagain River Hydro Limited 2,1722.5Owner and operator of a 1 MW hydro-power scheme in the Scottish Highlands Egress Software Technologies Limited 2,1142.4Encrypted email & file transfer service provider G.Network Communications Limited 1,8282.1Ultra-fast fibre optic broadband provider in central London Black Swan Data Limited 1,7402.0Predictive analytics for consumer brands Concirrus Limited 1,6321.9A software provider bringing real-time behavioural data analytics to the marine and transport insurance industries A full breakdown of the Company’s portfolio can be found on the Company’s webpage on the Manager’s website at www.albion.capital/funds/AATG, by following the ‘Portfolio of Investments’ link under the ‘Fund reports’ section.Material events and transactions after the period end After the period end, the Company undertook the following material investment transactions: * Our holding in SVS Albion OLIM UK Equity Income Fund was exited with total proceeds (including dividends) of £1.85 million on cost of £2.26 million; Proceeds of £757,000 received from the sale of Clear Review Limited on cost of £367,000; Investment of £283,000 in a new portfolio company, Seldon Technologies Limited, a software company that enables enterprises to deploy Machine Learning models in production; Investment of £180,000 in an existing portfolio company, Limitless Technology Limited, a provider of a customer service platform powered by the crowd and machine learning technology; * Investment of £100,000 in a new portfolio company, uMedeor Limited (T/A uMed), a middleware technology platform that enables life science organisations to conduct medical research programmes; and * Investment of £84,000 in an existing portfolio company, Arecor Limited, which develops biopharmaceuticals through the application of a formulation technology platform.There have been no further significant events or transactions between 1 October 2020 and 11 November 2020 that the Board is aware of which would have had a material impact on the financial position of the Company.Further information Further information regarding historic and current financial performance and other useful shareholder information can be found on the Company’s webpage on the Manager’s website at www.albion.capital/funds/AATG.Dr. Neil Cross, Chairman 11 November 2020 For further information please contact: Albion Capital Group LLP – tel: 020 7601 1850

Source: https://au.finance.yahoo.com/news/bmw-announces-ix-next-gen-130003526.html

Bayerische Motoren Werke AG, Electric vehicle, Sport utility vehicle

World news – US – BMW announces the iX, its next-gen electric flagship

Building on its expertise in the areas of digital, technologies and processes , CSS Engineering you in your most ambitious transformation projects and helps you bring out new ideas, new offers, new modes of collaboration, new ways of producing and selling.

CSS Engineering is involved in projects each customer as if it were his own. We believe a consulting company should be more than an advisor. We put ourselves in the place of our customers, to align we incentives to their goals, and collaborate to unlock the full potential their business. This establishes deep relationships and enjoyable.

Our services:

  1. Create professional websites
  2. Hosting high performance and unlimited
  3. Sale and video surveillance cameras installation
  4. Sale and Installation of security system and alarm
  5. E-Marketing

All our achievements here https://www.css-engineering.com/en/works/

LEAVE A REPLY

Please enter your comment!
Please enter your name here